Pfizer feels the pain as two Lyrica Phase III studies send out a negative vibe
This article was originally published in Scrip
Executive Summary
Pfizer stopped one Phase III clinical trial for Lyrica (pregabalin) in neuropathic pain and announced a missed endpoint in another, but will continue to seek new indications for the blockbuster drug.